<p>分析师对 Beta Bionics (NASDAQ: BBNX) 在过去一个季度的评级从看涨到看跌不等，共有 4 位分析师提供了相关信息。</p>
<p>下表提供了他们最近评级的快照，展示了过去 30 天情绪的演变，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师为 Beta Bionics 设定了 12 个月的价格目标，显示出平均目标为 31.75 美元，最高预估为 40.00 美元，最低预估为 17.00 美元。当前的平均值比之前的平均价格目标 32.33 美元下降了 1.79%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769536867_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769536867_0.png"/></p>
<h2>解读分析师评级：详细分析</h2>
<p>对金融专家如何看待 Beta Bionics 的全面审查源于最近的分析师行动。以下是关键分析师、他们最近的评估以及对评级和价格目标的调整的详细总结。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mathew Blackman</td>
<td>TD Cowen</td>
<td>宣布</td>
<td>持有</td>
<td>17.00 美元</td>
<td>-</td>
</tr>
<tr>
<td>Frank Takkinen</td>
<td>Lake Street</td>
<td>上调</td>
<td>买入</td>
<td>40.00 美元</td>
<td>35.00 美元</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>上调</td>
<td>买入</td>
<td>33.00 美元</td>
<td>30.00 美元</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>上调</td>
<td>买入</td>
<td>37.00 美元</td>
<td>32.00 美元</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师对市场条件和公司表现的变化作出反应，频繁更新他们的建议。无论是 '维持'、'上调' 还是 '下调' 他们的立场，都反映了他们对与 Beta Bionics 相关的最新发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 提供全面视角，分析师对股票进行定性评估，从 '跑赢大盘' 到 '跑输大盘'。这些评级传达了对 Beta Bionics 相对于更广泛市场的表现预期。</li>
<li><strong>价格目标：</strong> 分析师提供对 Beta Bionics 股票未来价值的估计，揭示了分析师预期随时间变化的趋势。</li>
</ul>
<p>将这些分析师评估与关键财务指标结合起来，可以提供 Beta Bionics 市场地位的全面概述。保持信息灵通，并在我们的评级表的帮助下做出明智的决策。</p>
<p>随时了解 Beta Bionics 的分析师评级。</p>
<p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
<h2>更好地了解 Beta Bionics</h2>
<p>Beta Bionics Inc 是一家商业阶段的医疗设备公司，致力于设计、开发和商业化解决方案，以改善需要胰岛素的糖尿病患者（PWD）的健康和生活质量，利用自适应闭环算法简化和改善他们的疾病治疗。公司的产品包括 iLet 电子胰腺 (iLet)。该公司作为一个单一业务部门运营，专注于 iLet 的开发、制造和销售。</p>
<h3>财务里程碑：Beta Bionics 的历程</h3>
<p><strong>市值分析：</strong> 公司的市值低于行业基准，相对于同行反映出较小的规模。这可能归因于增长预期或运营能力等因素。</p>
<p><strong>收入增长：</strong> Beta Bionics 在 3M 的出色表现显而易见。截至 2025 年 9 月 30 日，该公司实现了 <strong>63.14%</strong> 的令人印象深刻的收入增长率。这标志着公司顶线收益的显著增加。与竞争对手相比，该公司的增长率高于医疗保健行业同行的平均水平。</p>
<p><strong>净利润率：</strong> Beta Bionics 的净利润率令人印象深刻，超过行业平均水平。净利润率为 <strong>-52.14%</strong>，公司展现出强大的盈利能力和有效的成本管理。</p>
<p><strong>股本回报率 (ROE)：</strong> 公司的 ROE 表现突出，超过行业平均水平。ROE 为 <strong>-4.76%</strong>，公司展示了有效利用股本的能力。</p>
<p><strong>资产回报率 (ROA)：</strong> Beta Bionics 的 ROA 突出，超过行业平均水平。ROA 为 <strong>-4.31%</strong>，公司展示了有效利用资产和强大的财务表现。</p>
<p><strong>债务管理：</strong> Beta Bionics 的债务与股本比率为 <strong>0.03</strong>，低于平均水平，采用谨慎的财务策略，表明其在债务管理方面的平衡方法。</p>
<h2>分析师评级是如何确定的？</h2>
<p>评级来自分析师，或在银行和金融系统内的专家，他们为特定股票或定义的行业报告（通常每季度一次）。分析师通常从公司电话会议和会议、财务报表以及与重要内部人士的对话中获取信息，以做出决策。</p>
<p>一些分析师发布他们对增长预期、收益和收入等指标的预测，以提供额外的指导。当使用分析师评级时，重要的是要记住，股票和行业分析师也是人，他们只是向投资者提供自己的意见。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>

BBNX

<p>分析师对 Beta Bionics（NASDAQ:BBNX）的评级显示出看涨和看跌情绪的混合。最近的评估表明，12 个月的平均目标价格为 31.75 美元，低于 32.33 美元。主要分析师提高了他们的评级，目标价格范围从 17.00 美元到 40.00 美元不等。该公司专注于开发糖尿病管理解决方案，报告的收入增长率为 63.14%，并保持 0.03 的低债务股本比率，反映出谨慎的财务管理。分析师的评级基于市场状况和公司表现，为 Beta Bionics 的市场地位提供了洞察</p>

<p>Analysts' ratings for Beta Bionics (NASDAQ: BBNX) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<div class="lb-trans"><p>分析师对 Beta Bionics (NASDAQ: BBNX) 在过去一个季度的评级从看涨到看跌不等，共有 4 位分析师提供了相关信息。</p>
</div><p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他们最近评级的快照，展示了过去 30 天情绪的演变，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts have set 12-month price targets for Beta Bionics, revealing an average target of $31.75, a high estimate of $40.00, and a low estimate of $17.00. This current average represents a 1.79% decrease from the previous average price target of $32.33.</p>
<div class="lb-trans"><p>分析师为 Beta Bionics 设定了 12 个月的价格目标，显示出平均目标为 31.75 美元，最高预估为 40.00 美元，最低预估为 17.00 美元。当前的平均值比之前的平均价格目标 32.33 美元下降了 1.79%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769536867_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769536867_0.png"/></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<div class="lb-trans"><h2>解读分析师评级：详细分析</h2>
</div><p>A comprehensive examination of how financial experts perceive Beta Bionics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>对金融专家如何看待 Beta Bionics 的全面审查源于最近的分析师行动。以下是关键分析师、他们最近的评估以及对评级和价格目标的调整的详细总结。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mathew Blackman</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>Frank Takkinen</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$37.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mathew Blackman</td>
<td>TD Cowen</td>
<td>宣布</td>
<td>持有</td>
<td>17.00 美元</td>
<td>-</td>
</tr>
<tr>
<td>Frank Takkinen</td>
<td>Lake Street</td>
<td>上调</td>
<td>买入</td>
<td>40.00 美元</td>
<td>35.00 美元</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>上调</td>
<td>买入</td>
<td>33.00 美元</td>
<td>30.00 美元</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>上调</td>
<td>买入</td>
<td>37.00 美元</td>
<td>32.00 美元</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Beta Bionics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Beta Bionics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Beta Bionics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师对市场条件和公司表现的变化作出反应，频繁更新他们的建议。无论是 '维持'、'上调' 还是 '下调' 他们的立场，都反映了他们对与 Beta Bionics 相关的最新发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 提供全面视角，分析师对股票进行定性评估，从 '跑赢大盘' 到 '跑输大盘'。这些评级传达了对 Beta Bionics 相对于更广泛市场的表现预期。</li>
<li><strong>价格目标：</strong> 分析师提供对 Beta Bionics 股票未来价值的估计，揭示了分析师预期随时间变化的趋势。</li>
</ul>
</div><p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Beta Bionics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<div class="lb-trans"><p>将这些分析师评估与关键财务指标结合起来，可以提供 Beta Bionics 市场地位的全面概述。保持信息灵通，并在我们的评级表的帮助下做出明智的决策。</p>
</div><p>Stay up to date on Beta Bionics analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Beta Bionics 的分析师评级。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
</div><h2>Get to Know Beta Bionics Better</h2>
<div class="lb-trans"><h2>更好地了解 Beta Bionics</h2>
</div><p>Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.</p>
<div class="lb-trans"><p>Beta Bionics Inc 是一家商业阶段的医疗设备公司，致力于设计、开发和商业化解决方案，以改善需要胰岛素的糖尿病患者（PWD）的健康和生活质量，利用自适应闭环算法简化和改善他们的疾病治疗。公司的产品包括 iLet 电子胰腺 (iLet)。该公司作为一个单一业务部门运营，专注于 iLet 的开发、制造和销售。</p>
</div><h3>Financial Milestones: Beta Bionics's Journey</h3>
<div class="lb-trans"><h3>财务里程碑：Beta Bionics 的历程</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值低于行业基准，相对于同行反映出较小的规模。这可能归因于增长预期或运营能力等因素。</p>
</div><p><strong>Revenue Growth:</strong> Beta Bionics's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of <strong>63.14%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> Beta Bionics 在 3M 的出色表现显而易见。截至 2025 年 9 月 30 日，该公司实现了 <strong>63.14%</strong> 的令人印象深刻的收入增长率。这标志着公司顶线收益的显著增加。与竞争对手相比，该公司的增长率高于医疗保健行业同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Beta Bionics's net margin is impressive, surpassing industry averages. With a net margin of <strong>-52.14%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Beta Bionics 的净利润率令人印象深刻，超过行业平均水平。净利润率为 <strong>-52.14%</strong>，公司展现出强大的盈利能力和有效的成本管理。</p>
</div><p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-4.76%,</strong> the company showcases effective utilization of equity capital.</p>
<div class="lb-trans"><p><strong>股本回报率 (ROE)：</strong> 公司的 ROE 表现突出，超过行业平均水平。ROE 为 <strong>-4.76%</strong>，公司展示了有效利用股本的能力。</p>
</div><p><strong>Return on Assets (ROA):</strong> Beta Bionics's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-4.31%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<div class="lb-trans"><p><strong>资产回报率 (ROA)：</strong> Beta Bionics 的 ROA 突出，超过行业平均水平。ROA 为 <strong>-4.31%</strong>，公司展示了有效利用资产和强大的财务表现。</p>
</div><p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.03</strong>, Beta Bionics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Beta Bionics 的债务与股本比率为 <strong>0.03</strong>，低于平均水平，采用谨慎的财务策略，表明其在债务管理方面的平衡方法。</p>
</div><h2>How Are Analyst Ratings Determined?</h2>
<div class="lb-trans"><h2>分析师评级是如何确定的？</h2>
</div><p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<div class="lb-trans"><p>评级来自分析师，或在银行和金融系统内的专家，他们为特定股票或定义的行业报告（通常每季度一次）。分析师通常从公司电话会议和会议、财务报表以及与重要内部人士的对话中获取信息，以做出决策。</p>
</div><p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<div class="lb-trans"><p>一些分析师发布他们对增长预期、收益和收入等指标的预测，以提供额外的指导。当使用分析师评级时，重要的是要记住，股票和行业分析师也是人，他们只是向投资者提供自己的意见。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>
</div>

超越数字：四位分析师讨论 Beta Bionics 的股票